Researcher Profile

Robert S. DiPaola, MD

Center Director, Rutgers Cancer Institute of New Jersey and Associate Dean for Oncology Programs
Professor of Medicine, Medical Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-8064
Email: dipaolrs@cinj.rutgers.edu

Assistant: Allison Warzala
(732) 235-3336
Email: warzalab@cinj.rutgers.edu

Resident Member, Rutgers Cancer Institute of New Jersey


Research Program Alignment

Membership Type: Full


Research Interests

  • Apoptosis
  • Autophagy
  • Drug resistance mechanisms in Prostate Cancer
  • Translational Research
  • Chairman of GU commiittee of ECOG

Selected Publications

Hudson SV, Miller SM, Hemler J, Ferrante JM, Lyle J, Oeffinger KC, DiPaola RS. Adult Cancer Survivors Discuss Follow-up in Primary Care: 'Not What I Want, But Maybe What I Need'. Ann Fam Med. 2012 Sep;10(5):418-27. PubMed PMID: 22966105; PubMed Central PMCID: PMC3438209.

Saleem A, Dvorzhinski D, Santanam U, Mathew R, Bray K, Stein M, White E, DiPaola RS. Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012 Sep 1;72(12):1374-81. doi: 10.1002/pros.22487. Epub 2012 Jan 12. PubMed PMID: 22241682.

Lin H, Gounder MK, Bertino JR, Kong AN, DiPaola RS, Stein MN. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal. 2012 Jul;66:371-5. Epub 2012 Mar 24. PubMed PMID: 22483642; PubMed Central PMCID: PMC3358459.

Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Does Primary Androgen-Deprivation Therapy Delay the Receipt of Secondary Cancer Therapy for Localized Prostate Cancer? Eur Urol. 2012 May 10. [Epub ahead of print] PubMed PMID: 22608160.

Gounder MK, Lin H, Stein M, Goodin S, Bertino JR, Kong AN, DiPaola RS. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr. 2012 May;26(5):650-4. doi: 10.1002/bmc.1710. Epub 2011 Sep 19. PubMed PMID: 21932382.

Stein MN, Goodin S, DiPaola RS. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res. 2012 Apr 1;18(7):1848-54. Epub 2012 Mar 26. Review. PubMed PMID: 22451619.

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit. 2012 Apr;18(4):CR260-4. PubMed PMID: 22460098.

Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J, Chen HY, Ghavami A, Stein M, DiPaola RS, Zhang D, Rabinowitz JD, White E. Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition. PLoS One. 2012;7(7):e41831. Epub 2012 Jul 26. PubMed PMID: 22848625; PubMed Central PMCID: PMC3406086.

Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.Invest New Drugs. 2011 Dec;29(6):1432-40. Epub 2010 Mar 25. Erratum in: InvestNew Drugs. 2011 Dec;29(6);1517-8. Cooney, Kathleen A [added]; Mathew, Paul [added]; Pienta, Kenneth J [added]; Escara-Wilke, June [added]; Doyle, Gerald [added]; Al-Hawary, Mahmoud [added]; Keller, Evan T [added]. PubMed PMID: 20336348; PubMed Central PMCID: PMC2917503.

Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V, Coller HA, DiPaola RS, Gelinas C, Rabinowitz JD, White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011 Mar 1;25(5):460-70. Epub 2011 Feb 11. PubMed PMID: 21317241; PubMed Central PMCID: PMC3049287.

Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15;17(4):654-66. Review. PubMed PMID: 21325294; PubMed Central PMCID: PMC3075808.

Delnevo CD, Steinberg MB, Hudson SV, Ulpe R, DiPaola RS. Epidemiology of Cigarette and Smokeless Tobacco Use among South Asian Immigrants in the Northeastern United States. J Oncol. 2011;2011:252675. Epub 2011 May 17. PubMed PMID: 21772842; PubMed Central PMCID: PMC3136136.

Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, DiPaola RS. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.Prostate. 2010 Sep 15;70(13):1388-94. PubMed PMID: 20687211.

Parekh N, Lin Y, DiPaola RS, Marcella S, Lu-Yao G. Obesity and prostate cancer detection: insights from three national surveys. Am J Med. 2010 Sep;123(9):829-35. PubMed PMID: 20800152.

Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med. 2010 Jul 26;170(14):1256-61. PubMed PMID: 20660846.

DiPaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med. 2010 Feb 24;8:20. PubMed PMID: 20178647; PubMed Central PMCID: PMC2837641.

Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, DiPaola RS, Lu-Yao GL. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3. Epub 2009 Aug 27. PubMed PMID: 19713548; PubMed Central PMCID: PMC2744729.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA. 2009 Sep 16;302(11):1202-9. PubMed PMID: 19755699; PubMed Central PMCID: PMC2822438.

White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009 Sep 1;15(17):5308-16. Epub 2009 Aug 25. Review. PubMed PMID: 19706824; PubMed Central PMCID: PMC2737083.

Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E. Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res. 2009 Sep;7(9):1487-96. Epub 2009 Sep 8. PubMed PMID: 19737977; PubMed Central PMCID: PMC2855683.

Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, DiPaola RS, Karantza-Wadsworth V, White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009 Jun 12;137(6):1062-75. Erratum in: Cell. 2011 Apr 15;145(2):322. PubMed PMID: 19524509; PubMed Central PMCID: PMC2802318.

Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20;27(15):2450-6. Epub 2009 Apr 20. PubMed PMID: 19380444; PubMed Central PMCID: PMC2684851.

Jiang Y, DiPaola RS, Hu L. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorg Med Chem Lett. 2009 May 1;19(9):2587-90. Epub 2009 Mar 9. PubMed PMID: 19345094.

The content for this Research Profile is maintained by Paul Novembre (novembre@cinj.rutgers.edu)